Company Intelligence

Probably Genetic

Probably Genetic is changing the lives of patients living with severe, complex diseases. Our data platform is used by drug developers and patient advocacy groups to develop and launch treatments for these patients. Our technology discovers…

In this profile

Quick Facts

  • Founded 2019
  • Headquarters San Francisco, United States
  • Country United States
  • Industry AI in Healthcare
  • Company Type Growth
  • Status Active
  • Website Official site
  • Last Reviewed Jul 2026

Executive Summary

Probably Genetic is changing the lives of patients living with severe, complex diseases. Our data platform is used by drug developers and patient advocacy groups to develop and launch treatments for these patients. Our technology discovers undiagnosed patients online, analyzes their disease state using machine learning and at-home testing, and enables compliant communication with patients. In doing so, we help patients access diagnoses, clinical trials, and treatments as early as possible.

Why It Matters

Patient Intelligence Platform for Genetic Disease

Recent Developments

  1. 2019 Company founded

    Probably Genetic was founded in 2019 per the company profile source on file.

    Source

Connected Reports

Connected Insights

Industries

Probably Genetic is changing the lives of patients living with severe, complex diseases. Our data platform is used by drug developers and patient advocacy groups to develop and launch treatments for these patients. Our technology discovers undiagnosed patients online, analyzes their disease state using machine learning and at-home testing, and enables compliant communication with patients. In doing so, we help patients access diagnoses, clinical trials, and treatments as early as possible.

Company information is based on publicly available sources and is reviewed periodically. If you represent this company and would like to request a correction, contact Brel.

Explore Related Intelligence

The AI Brief

Weekly company intelligence in your inbox.

Subscribe